series-c-plus
Stage
1
Investors
About
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies that modulate gene expression to treat genetically defined rare diseases, including sickle cell disease through its lead program pociredir.
Explore Fulcrum Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.